AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Subscribe To Our Newsletter & Stay Updated